 |
|
Inhibition of Experimental Mammary CarcinomaAutologous Intrasplenic Ovarian Transplant
Frederick A. Reichle, MD;
Margot Gruenstein;
Rose Marie Reichle, MEd;
David R. Meranze, MD;
George P. Rosemond, MD;
Michael B. Shimkin, MD
AMA Arch Surg. 1972;104(2):206-208.
Abstract
Intrasplenic ovarian autotransplantation is associated with significant inhibition of 7,12-dimethylbenz (a) anthracene-produced breast carcinoma in the rat. The mechanism of this inhibition may be related to the position of the transplanted ovary within the portal venous system, allowing initial drainage of ovarian venous efflux through the liver. Hepatic alteration of ovarian hormones could result in changes in hormone concentration within the mammary gland, and this may represent the mechanism of inhibition of tumorigenesis. End-to-side portacaval shunt done simultaneously with intrasplenic ovarian transplantation is also associated with significant inhibition of experimental breast carcinoma. The previously observed inhibition of experimental breast carcinoma by end-to-side portacaval shunt alone has been reconfirmed.
Author Affiliations
Philadelphia
From the Department of Surgery and the Fels Research Institute of Temple University Health Sciences Center, Philadelphia.
Footnotes
Accepted for publication July 16, 1971.
Read before the annual meeting of the American Association for Cancer Research, Philadelphia, April 10, 1970.
Reprint requests to Temple University Health Sciences Center, 3401 N Broad St, Philadelphia 19140 (Dr. Reichle).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Ovariectomy in Rats With Portacaval Shunts: Reduction of Mammary Carcinoma
O'Grady et al.
Arch Surg 1974;109:87-88.
ABSTRACT
Effect of Portacaval Shunt on Tyrosine Metabolism
Reichle et al.
Arch Surg 1972;105:363-368.
ABSTRACT
|
